🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud to be a co-PI on this award with my wonderful collaborator, Greg Delgoffe Delgoffe Lab and mentor John M. Kirkwood

Thank you PA Medical Society for such an honor!

In #uveal #melanoma the OS of 15 months with ipi/nivo suggests that clinical benefit may larger than the modest ORR of 11.6%. @alexshoushtari Pauline Funchain Katy Tsai, MD @MunTheLoon John M. Kirkwood Dr Justine Cohen UPMC Hillman Cancer Center Journal for ImmunoTherapy of Cancer pubmed.ncbi.nlm.nih.gov/32581057/

“I am motivated every single day by my patients." -Dr. Yana Najjar, a physician-scientist who specializes in caring for individuals with melanoma and developing immunotherapy clinical trials. She also received a Hillman Fellowship in 2018. Learn more: hillmanresearch.upmc.edu/hillman-fellow…

Congrats to #melamona expert Diwakar Davar, M.D. the 2021 recipient of the Sy Holzer Endowed Immunotherapy Research Award for his innovative research in #Cancer #Immunotherapy! UPMC Pitt Health Sciences upmc.com/media/news/101…

via The New York Times Is Europe hiring melanoma specialists? Canada? Timbuktu?? nytimes.com/live/2023/06/3…

Representing our wonderful UPMC Hillman Cancer Center at the #SITC23 Gala! Robert Ferris, MD, PhD Riyue Sunny Bao, PhD Tullia Bruno, PhD Cyndy Patton Yana Najjar Delgoffe Lab Overacre Lab Diwakar Davar, M.D. Jason Luke, MD, FACP Michael Lotze

Coming up at #SITC23, Yana Najjar presents her study on improving treatment of metastatic melanoma. Session 208d: Oral Abstract Session | 5:05–6:30 p.m. | Ballroom 6CD. Pitt Health Sciences jitc.bmj.com/content/11/Sup…

Listen to our collaborator, Dr. Yana Najjar, speak today at #SITC: “Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors.” Session 208d, 5:05 PM, Upper Level, Ballroom 6CD

Hot off the press! Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations | Nature Reviews Immunology nature.com/articles/s4157…

I was delighted to present our translationally driven study at #SMR24 today. By reducing intra tumoral hypoxia, we see high rates of disease control in heavily pre-treated patients with #acral and #mucosal #melanoma. Society For Melanoma Research Delgoffe Lab